SEARLE, BOLAR AND LILLY LEAD DRUG STOCKS IN LACKLUSTER WEEK FOR "F-D-C" INDEX
Searle (up 2-1/8 to 49-1/8), Bolar (up 1-3/4 to 31-7/8) and Lilly (up 1-1/8 to 58) led the Pharmaceutical Component of the "F-D-C" Weekly Index to a fractional advance for the week ended Aug. 31. The Composite was flat at 493.1, while the Dow slipped 1% in the last week of August. Two other drug issues advanced a point: Robins (to 15-1/2) and Schering (to 37-5/8). The Chain group advanced 1.4% on healthy gains by Eckerd (up 2-1/8 to 25) and Revco (up 1-5/8 to 30-1/2). The battle for management control of Revco remained hot during the week (see related story, p. 7), and the company was one of the most actively traded stocks on the Street on Wednesday (volume 884,100 shares). The Diversified issues were lackluster during the week as only Johnson & Johnson (up 1-1/8 to 33-3/4) managed to climb more than a point. The Component dipped .3% as Novo (off 2-3/4 to 37-1/4), which slumped last week, continued to slide. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth